Generic Makers Fear Weakening Of Hatch-Waxman Rules

U.S. generic drug makers are wary of plans to reform the U.S. patent system, fearing that the powerful brand-name drug lobby will use the process to water down landmark legislation that...

Already a subscriber? Click here to view full article